HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
    • Archived Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Webinars / Adjusting for Differences in Tumor Assessment Schedules in Indirect Comparisons of Progression-Free Survival for HTAs

Adjusting for Differences in Tumor Assessment Schedules in Indirect Comparisons of Progression-Free Survival for HTAs

Event Date: Apr 30, 2020

Unanchored indirect treatment comparisons (ITCs) of progression-free survival (PFS) are becoming increasingly common in health technology assessments (HTAs), especially for novel cancer treatments approved using single-arm trials conducted in high unmet need populations. Disease progression is evaluated at tumor assessment visits scheduled over the course of follow-up in each trial. However, when the two studies included in an unanchored ITC of PFS use different assessment schedules, particularly for the first tumor assessment, the relative effect estimated from the comparison may be biased, favoring the treatment with later assessments. This type of bias is known as assessment-time bias (ATB).

Assessment schedule matching (ASM) aims to adjust time-to-event data to reflect what would have been observed if the study had followed the comparator’s assessment schedule for disease progression and can eliminate or substantially reduce ATB. Accounting for ATB can add valuable insight into the comparative assessment of PFS, minimize bias, provide a helpful addition to the analyses of data from clinical trials for novel cancer treatments, and ultimately inform clinical decision making.

Key Learning Objectives

By the end of this webinar, participants should be able to:

  • Recognize the potential bias in the estimation of progression-free survival (PFS) due to differences in the schedule of progression assessment between trials
  • Understand the key determinants of assessment-time bias (ATB) and how they affect its magnitude
  • Recognize when ASM is appropriate to use
  • Interpret results of indirect treatment comparisons with ASM
  • Describe assumptions and limitations of the ASM method

Click here for additional information and registration details.



You might also be interested in:

  • [Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
  • 2021 ARM - Call for Abstracts 01/13/2021
  • Inovalon to Support National Vaccine Adherence Programs… 11/09/2020
  • Research Considers Valuation of Indirect Benefits 05/13/2020
  • Using Bayesian Methods in Control Arms of Clinical Trials 02/18/2021
  • HTA in the USA: ICER vs NICE 09/11/2020
  • Eversana Partners on Research Data Assessment 08/11/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters

Syndicated Reports

Artificial Intelligence in Healthcare Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Component, Application, End User, and Geography

Healthcare Trends & Forecasts in 2021: Performance Expectations for the Healthcare Industry

Medical Affairs Outsourcing Market 2021 Overview, Trends, Size, Growth and 2028 Future Insights

Bioinformatics Market Research Report by Product, by End User – Global Forecast to 2025 – Cumulative Impact of COVID-19

White Papers

What to Look for in an Informatics Platform for Life Sciences R&D

Beyond The Field: Evolving Field Medical Engagement And Talent For The Future

Innovating the Delivery of Patient Support: Branded Patient Support programs for Today’s Health Consumer

Healthcare Cost Containment: Best Practices & Recommendations

HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
    • Archived Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute